HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA’s Preferred Special Treatment For Cannabinoids Points To Mistreating Industry

Executive Summary

Senate bill provision allowing FDA to develop unique labeling and packaging for cannabinoid supplements and foods is unnecessary, as the products should following existing labeling regulations, says CRN chief Steve Mister.

You may also be interested in...



USPTO Cannabinoid Trademarks Approach Aligns With FDA Ingredient Regulation: Divert From Norm

Cannabinoid products have been available in US since at least 2012, when states began legalizing cannabis, but the earliest USPTO is recognizing submissions for those marks is December 2018 and it won’t register trademarks until FDA allows lawful use of the ingredients in non-drug products.

Mixing Food In Legislation Changing US FDA Cannabinoid Rules Could Choke Its Progress

Making lawful the use of hemp cannabinoids in supplements and food is a step in the right direction, but including food may doom it, say industry stakeholders. As well, CRN CEO Steve Mister notes FDA has stated reservations about using cannabinoids in food.

US Senate Appetite For Lawful Use Of Cannabinoids Includes Food On Top Of Supplements

Senate bill introduced on 19 May, unlike a House bill introduced in February, would direct FDA to allow using hemp-derived cannabinoids in food products as well as supplements. However, neither bill includes language on setting a safe daily level that some industry stakeholders argue is needed.

Related Content

Topics

UsernamePublicRestriction

Register

RS151372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel